An interventional study of pneuRIP (breathing with resistance) and Respitrace system (Carefusion) (breathing without resistance) in Neuromuscular Diseases and Healthy Volunteers, sponsored by Nemours Children's Clinic. Recruiting at 1 site in United States. Open to participants aged 11 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Nemours Children's Clinic · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.
Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 53rd largest by planned enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2014, is one of 23 with no phase, reaches primary completion later than 21 of the 38 other live ones, and was the 44th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18–70
David Toupin · Sites in United States
Ages 6–12
University of Pennsylvania · Sites in United States
Ages 18+
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Northwestern University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 11 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 20
First in 1984; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 30 across 204 interventional studies indexed under Neuromuscular Diseases.
Median enrollment 48 across the 72 interventional studies, 82 across the 46 observational. Of the 77 that completed or were terminated, 28 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 120 have an industry lead sponsor. The 10 most frequent:
Nemours Children's Clinic is the lead sponsor of 130 studies on the registry; 26 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Nemours Children's Clinic has 2 studies filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuromuscular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT06970522Shirley Ryan AbilityLabWearable Sensors to Detect Atypical Muscle Activation in Young Infants | 2026-12-31 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07223632Vanda PharmaceuticalsTreatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 120 studies in Neuromuscular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will clinically evaluate a newly developed respiratory monitor - pneuRIP. The pneuRIP uses Respiratory Inductance Plethysmography (RIP) bands to measure key breathing indices non-invasively. This study compares the pneuRIP to an existing Respitrace system (Carefusion, Yorba Linda CA). 10 normal children and 10 children with breathing difficulties will be monitored with both systems.
Firstly, ten healthy children will participate in a trial to evaluate the pneuRIP. They will be fitted with the bands around their abdomen and chest. The pneuRIP will be connected to the bands through electrodes. Breathing is then measured wirelessly with an iPad. They will be asked to lie down. They are asked to breath normally then asked to breath with a resistive elements to place in their mouth. The resistive elements makes it difficult to breath (similar to breathing through a straw). They will breathe for 3 minutes for both conditions as we record their breathing with the pneuRIP and the Respitrace. These data will be compared.
Secondly, A group of 10 subjects from the outpatient muscle clinic will be fitted with the chest and abdomen bands. The Respitrace monitor and the pneuRIP will record their breathing patterns. Data from the two systems will then be compared.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Testing the subjects breathing with resistance
Device: pneuRIP (breathing with resistance) · Device: Respitrace system (Carefusion) (breathing without resistance)
Testing subjects breathing without resistance
subjects are given a resistance element to breath through
subjects are asked to breath normally
Breathing rate
The breathing rate is measured by two different monitors
Time frame: Immediately after test
Labored breathing Index
The labored breathing index is measured by two different monitors
Time frame: Immediately after test
Phase Difference
The phase difference between the pneuRIP and Respitrace is measured by two different monitors
Time frame: Immediately after test
Percent rib cage
The percentage of breathing performed by the rib cage is measured by two different monitors
Time frame: Immediately after test
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2014 (actual). Primary completion is estimated for Dec 2027, 160 months after the start.
Of 75 non-industry interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 47. This study's planned 160 months is above that.
Counting every sponsor, half of 84 studies reached it within 25 months; a quarter within 12 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.